Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universitë De Bordeaux

Université Grenoble Alpes

Université Claude Bernard Lyon I

Nanoh

Commissariat &#xc0; L'&#xc9;nergie Atomique Et Aux &#xc9;nergies Alternatives

Commissariat a L'energie Atomique

Université Joseph Fourier

The Joseph Fourier University of Grenoble

Jean-Luc Coll

Olivier Tillement

Isabelle Texier-Nogues

Pascal Dumy

Didier Boturyn

Yannick Cremillieux

Andrea Bianchi

Sandrine Dufort

Anne Imberty

Véronique Robert

Marie Favrot

Marie-Christine Favrot

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Ultrafine nanoparticles as multimodal contrast agent

The invention concerns the field of molecular probe architecture for in vivo imaging. More particularly, the invention concerns molecular constructs providing an imaging function activable in intracellular environment. The inventive fluorescence probes enable in particular images of certain targeted tissues to be formed, while maintaining a low background noise level and, preferably, while obtaining at the targeted tissue, an imaging signal increasing in time.

Target vector with activable imaging function

A fluorescent enzymatic substrate including a backbone saccharide nature having at least one saccharide unit. The saccharide unit includes a fluorophore Fand an inhibitor Iof the fluorescence of F. The fluorophore Fand the inhibitor I, either directly or by the spacer arms Band B, respectively, when at least one Band Bis present, are grafted on the same saccharide unit of the backbone saccharide. One of th groups is Fand Igrafted in the anomeric position 1 of the saccharide unit.

Saccharide fluorescent substrates, preparation method and uses thereof

A method for preparing a grafted homodetic cyclopeptide forming a framework that defines a grafted upper face and grafted lower face, including synthesizing a linear peptide from modified or unmodified amino acids, some of which carry orthogonal protective groups; intramolecular cyclizing the resulting protected linear peptide; substituting some or all of orthogonal protective groups with a protected precursor; and grafting at least one molecule of interest onto one and/or the other face of the framework via an oxime bond.

Synthesis and characterization of novel systems for guidance and vectorization of molecules of therapeutic interest towards target cells

Growing community of inventors

Claix, France

Jean-Luc Coll